BTW, Kogelnik is planning a trial of rituximab, in conjunction with antivirals. His thought is that the B-cells may be reservoirs for active viruses, and that killing them off helps to get rid of active virus infections. I guess that antivirals can't get at the viruses in the B-cells. (Though this article notes that there is little evidence of active viral infection in these patients.) He thinks that the B-cells may get slowly reinfected afterward, leading to the recurrence of symptoms. His hope is that by combining the two, it would be possible to completely eliminate symptoms.
I don't know when that trial will begin, though. He told me that he has a trial of a number of antivirals and immune modulators that he hopes will start in March, but I don't know whether that will include rituximab. When I spoke with him about it a couple of months ago, it sounded like it might take a bit longer to get the rituximab trial started.